Kai Grass
Partner,
Passionate about Healthcare, Corporate M&A and Divestitures with global experience in developed and emerging markets
Kai
専門分野
- Interlock for M&A in Healthcare & Life Sciences
- Co-author of Bain's 2023 M&A Report
Kai Grass is a member of our Healthcare & Life Sciences and M&A & Divestitures practices.
Kai’s healthcare work focuses on pharmaceutical and medtech clients. He has extensive experience in biopharma strategy and transformation in different topics such as R&D and clinical trials, M&A, commercial, pricing, and product launch, and emerging markets trends.
His recent client engagements have focused heavily on M&A and Divestiture topics for clients across industries. He is an authority on post-merger integration, carve-out/divestitures and separations, corporate M&A strategy and capability building, as well as value creation plans in post-acquisition situations.
Prior to joining the firm in 2009, he held research roles at Procter & Gamble and various academic institutions.
He holds a Ph.D. in Theoretical Physics from Goethe University, a diploma in physics from the University of Freiburg and a diploma in applied physics from the University of Auckland.
Recent Insights
- “Key Insights from Bain’s 2024 M&A Report,” Webinar, 2024年2月29日
- “Healthcare and Life Sciences M&A,” M&A Report, 2024年1月30日, レポート
- “Looking Back at M&A in 2023: Who Wins in a Down Year?,” M&A Report, 2024年1月30日, レポート
- “Looking Ahead: How the Big Backlog Will Shape the 2024 M&A Agenda,” M&A Report, 2024年1月30日, レポート
- “Three Prescriptions for the Future of Biopharma Productivity,” 論説, 2023年7月18日